[Clinical and epidemiological characteristics of XXXX in adults according to the data of municipal hematology departments in Moscow].

@entity1 @entity4557 @entity3052 @entity2592 @entity7730 @entity204
AIM: To estimate the incidence of @entity3052 ( @entity3052 ) in Moscow adults and to evaluate the efficiency of their treatment. SUBJECTS AND METHODS: Data on Moscow residents who were first diagnosed with @entity3052 in 2010 were retrospectively collected. The efficiency of their treatment was evaluated from the rates of complete remissions (CR), recurrences, @entity204 , and 4-year overall (OS) and @entity4557 ( @entity4557 ). The data as of September 1, 2013, were analyzed. RESULTS: According to the 2010 pooled materials of the city's municipal hematology departments, @entity3052 (non-M3 types) was diagnosed in 286 @entity1 whose median age at diagnosis was 64.9 years (range, 18.2-92.0 years). The notified incidence rate was 2.9 (3.3 for @entity1 and 2.6 for @entity1 ) cases per 100,000 population. 118 (41%) @entity1 received @entity7730 ( @entity7730 ); 119 (42%) had chemotherapy with low-dose @entity2592 (LDC); 7 (2%) had that with hypomethylating agents (HA); and 42 (15%) had palliative therapy (PT). During first-line therapy, none of the @entity1 underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the entire group, the early (within the first 60 days) mortality rates were 42% (119 @entity204 ); that of @entity1 with primary refractory disease was 32% (90 @entity204 ). CR was achieved in 77 (27%) @entity1 : 57 (48%) on @entity7730 , 17 (14%) on LDC, and 3 (43%) on HA. Recurrences occurred in 37 (48%) of the 77 @entity1 who had achieved CR at a median follow-up of 43.9 months. Four-year OS in all the @entity1 receiving PT was 9.8  1.9% (18.2  3.9% in the @entity1 on @entity7730 versus 4.5  2% in those of LDC; p=0.028); 4-year @entity4557 was 36.1  5.7% (39.6  6.7% inthe @entity1 on @entity7730 versus 31.3  11 .6% in those on LDC; p=0.8). CONCLUSION: High mortality rates in the induction, which are caused by the limited resources of accompanying therapy, poor sanitary conditions, and no own opportunities to perform allo-HSCT, remain a key problem of @entity3052 therapy in adults.
